Key Highlights
- On July 22, 2026, Lakewood-Amedex Biotherapeutics (LABT) unveiled resistance study results for Nu-3, its Phase 2-ready antimicrobial compound.
- Serial passage experiments demonstrated Nu-3’s inability to trigger resistance development.
- The compound is being developed for infected diabetic foot ulcers and functions through a physical membrane-disruption mechanism.
- Laboratory studies confirmed efficacy against numerous resistant bacterial strains, including MRSA and VRE.
- Trading at $1.86 near its 52-week low, LABT maintains a market capitalization of approximately $3.26 million.
On July 22, 2026, Lakewood-Amedex Biotherapeutics (LABT) unveiled fresh resistance study findings for its primary antimicrobial asset, Nu-3. The announcement triggered a dramatic market response, with shares climbing more than 141% during the trading session.
Lakewood-Amedex Biotherapeutics Inc. Common Stock, LABT
The clinical-stage biotechnology firm carries a modest market valuation of $3.26 million. Prior to the surge, shares were changing hands at $1.86, hovering near the 52-week bottom of $1.66.
Nu-3 belongs to the company’s proprietary Bisphosphocin antimicrobial platform. The compound targets treatment of diabetic foot ulcers with mild infections.
The standout discovery: Serial passage testing revealed Nu-3 failed to trigger resistance development. For a therapeutic aimed at antibiotic-resistant pathogens, this represents a significant finding.
Nu-3 employs a distinct approach from conventional antibiotics by physically compromising bacterial cell membranes. This physical mode of action presents substantial barriers to standard bacterial resistance evolution pathways.
In vitro studies demonstrated Nu-3’s effectiveness against bacterial strains harboring diverse resistance mechanisms. These encompassed modifications to antibiotic targets, direct antibiotic degradation, and efflux pump-mediated resistance.
Bacterial Strains Evaluated
Researchers examined 14 distinct bacterial species. The panel featured E. coli, S. aureus, P. aeruginosa, K. pneumoniae, and A. baumannii ā among the most challenging drug-resistant pathogens encountered in healthcare environments.
Resistance profiles analyzed included vanA and vanB genes, mecA, rpoB mutations, NDM carbapenemases, ESBL enzymes, AmpC Ī²-lactamases, CRE variants, sul2, and benzalkonium chloride efflux mechanisms. This represents comprehensive coverage of resistance pathways.
Testing also encompassed PBP2x alterations and metal-tetracycline/H+ antiporter-mediated resistance. In vitro results showed Nu-3 maintained activity against the complete spectrum.
Policy Context
This data release came after the 27th Public Meeting of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) on June 16, 2026. The session addressed the upcoming five-year National Action Plan on Combating Antibiotic-Resistant Bacteria.
Nu-3’s performance data corresponds with priorities established during that gathering, which established parameters for federal antimicrobial resistance initiatives.
Company insiders control 69.22% of shares, suggesting substantial confidence from management and key stakeholders.
No insider transaction activity has been documented over the previous three-month period.
LABT remains pre-revenue and continues to post losses. The company’s GF Score registers at 8 out of 100, with profitability metrics at 1/10 and financial strength assessed at 4/10.
Nu-3 has achieved Phase 2-ready status for treatment of mildly infected diabetic foot ulcers. The company has not yet disclosed a timeline for initiating Phase 2 studies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
